Skip Navigation

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Stratton, R. J.
Right arrow Articles by Black, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stratton, R. J.
Right arrow Articles by Black, C. M.
Related Collections
Right arrow Systemic Sclerosis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Rheumatology 2001; 40: 84-88
© 2001 British Society for Rheumatology

Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma

R. J. Stratton, H. Wilson and C. M. Black

Royal Free Hospital, London NW3 2QG, UK

Objective. To assess the safety and efficacy of anti-thymocyte globulin (ATG) followed by mycophenolate mofetil (MMF) in the treatment of diffuse scleroderma.

Methods. A pilot study of 13 patients with recent-onset diffuse scleroderma was carried out. Patients received ATG for 5 days, followed by MMF for 12 months. We recorded adverse events, scleroderma skin score, hand contractures, EuroQol score, scleroderma functional assessment, pulmonary function studies, echocardiogram and plasma creatinine concentration.

Results. Mean skin score decreased during the study from 28 at baseline to 17 after 12 months of MMF (P<0.01). Hand contractures worsened during the study. Mean measurements of systemic disease remained stable. One patient died after a scleroderma renal crisis. Five patients developed serum sickness after ATG treatment, but this was controlled by corticosteroid therapy. MMF therapy was well tolerated.

Conclusion. ATG and MMF appear safe in scleroderma. The improvement in skin score and the apparent stability of systemic disease during the study period suggest that controlled studies of these agents are justified.

KEY WORDS: Diffuse scleroderma, ATG, MMF.

Correspondence to: C. M. Black, Department of Rheumatology, Royal Free Hospital, London NW3 2QG, UK


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Rheumatology (Oxford)Home page
S. Chitale, J. Watson, and A. Herrick
Autologous skin grafting--a limb-saving procedure in a patient with diffuse cutaneous systemic sclerosis
Rheumatology, March 1, 2008; 47(3): 379 - 380.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. I. Nihtyanova, G. M. Brough, C. M. Black, and C. P. Denton
Mycophenolate mofetil in diffuse cutaneous systemic sclerosis--a retrospective analysis
Rheumatology, March 1, 2007; 46(3): 442 - 445.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. C. Plastiras, P. G. Vlachoyiannopoulos, and G. E. Tzelepis
Mycophenolate mofetil for interstitial lung disease in scleroderma
Rheumatology, December 1, 2006; 45(12): 1572 - 1572.
[Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
N. Blank, R. Max, and H.-M. Lorenz
The role of DMARDs in systemic sclerosis therapy
Rheumatology, October 1, 2006; 45(suppl_3): iii42 - iii44.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
S. N. C. Liossis, A. Bounas, and A. P. Andonopoulos
Mycophenolate mofetil as first-line treatment improves clinically evident early scleroderma lung disease
Rheumatology, August 1, 2006; 45(8): 1005 - 1008.
[Abstract] [Full Text] [PDF]

Home page
 Rheumatology (Oxford)Home page
A. M. Denman, R. Stratton, H. Wilson, and C. Black
Anti-thymocyte globulin in scleroderma
Rheumatology, October 1, 2001; 40(10): 1192 - 1192.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.